Aradigm Corp., of Hayward, Calif., said it was awarded a two-year phase II small business innovation research (SBIR) grant of approximately $972,000 by the National Institute of Allergy and Infectious Diseases and NIH to investigate the treatment of the pulmonary non-tuberculous mycobacteria (PNTM) infections, Mycobacterium avium and Mycobacterium abscessus, with its inhaled liposomal ciprofloxacin products, Linhaliq (formerly Pulmaquin) and Lipoquin.